NASDAQ$SGHT

Sight Sciences Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Reported financial results for the third quarter and withdrew its guidance for full year 2023.

Sight Sciences generated $20.0 million in total revenue, a 7% increase compared to the same period in the prior year. The company achieved a gross margin of 86.6% and is implementing a plan to reduce operating expenses and improve cost efficiencies.

  • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
  • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
  • Appointed new Chief Commercial Officer, Matt Link, to lead commercial strategy and advance growth initiatives.
  • Implemented a plan to reduce operating expenses, improve cost efficiencies, and further extend cash runway with an approximate 10% reduction in force (estimated $7.9 million annualized savings) and other cost saving initiatives (estimated $5.0 million annualized savings).

Headline financials

Total Revenue

$20M

Previous: $18.7M+7.1%
EPS (adj)

-$0.27

Previous: -$0.46+41.3%
Total Gross Margin

86.6%

Previous: 84.0%+3.1%
Capital Expenditures

-$527K

Previous: -$841K+37.3%
Free Cash Flow

-$13.6M

Previous: -$23.1M+41.2%
Net Income

-$13M

Previous: -$22.2M+41.4%
Operating Income

-$13.4M

Previous: -$21.8M+38.6%
Gross Profit

$17.3M

Previous: $15.7M+10.1%
Cash & Equivalents

$145M

Previous: $200M-27.7%
Total Assets

$177M

Previous: $225M-21.6%
R&D Expense

$4.24M

No prior period
Stock-Based Comp

$3.86M

Previous: $3.22M+19.6%

Revenue & EPS history

Sight Sciences · Revenue · Quarterly

$20M

Q3 2023+7.1%vs Q3 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Sight Sciences · $20M total across 2 segments · Q3 2023

  • Interventional Glaucoma
    $18.4M+7.6%
  • Interventional Dry Eye
    $1.6M+0.0%

Forward guidance

Sight Sciences withdraws its previous full year 2023 revenue and adjusted operating expense guidance expectations due to the uncertainty caused by the final LCD published by WPS and the proposed LCDs issued by four other MACs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+3.0%

Avg return

Earnings day

+4.0%

Avg return

5 days after

+5.0%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+60.9%

Q3 2022

Best reaction

-26.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.7%+22.6%+2.5%
Q4 2025-26.9%-25.9%-34.9%
Q3 2025+16.0%+54.4%+61.0%
Q1 2025+1.3%+8.3%+38.6%
Q4 2024+2.9%+15.3%-5.0%
Q3 2024-17.1%-17.1%-24.1%
Q2 2024-18.9%-29.4%-13.0%
Q1 2024+6.6%+1.1%+17.4%
Q4 2023+6.8%-4.4%+21.4%
Q3 2023+19.8%+2.0%+54.1%
Q2 2023+11.0%+4.1%-16.0%
Q1 2023-0.4%+0.6%-25.1%
Q4 2022+4.9%-2.3%-5.8%
Q3 2022+60.9%+50.4%+72.9%
Q2 2022-3.9%-16.1%-26.2%
Q1 2022+11.2%+23.9%+59.2%
Q4 2021-10.1%-6.1%-45.5%
Q3 2021-2.4%-5.8%-20.6%
Q2 2021-4.7%+0.1%-15.9%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro